Skip to main content

Table 1 Cost of providing RSV immunoprophylaxis to Infants by Risk Group (assuming 100% coverage)

From: Should we use Palivizumab immunoprophylaxis for infants against respiratory syncytial virus? – a cost-utility analysis

Risk group % of births Births in 2015 Vaccination Cost USD
CHD 0.03% 50 314,057
CLD 0.12% 217 1,360,912
<29 0.42% 753 4,731,498
29–32 0.88% 1570 9,862,078
33–36 6.13% 10,956 68,814,325
No risk 92.42% 165,177 1,037,499,916